# A Study of Chemoimmunotherapy for the Treatment of Men With Neuroendocrine or Aggressive Variant Metastatic Prostate Cancer

> **NCT04709276** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Andrew J. Armstrong, MD** · enrollment: 41 (actual)

## Conditions studied

- Metastatic Prostate Neuroendocrine Carcinoma
- Metastatic Prostate Cancer

## Interventions

- **DRUG:** Nivolumab
- **DRUG:** Ipilimumab
- **DRUG:** Carboplatin
- **DRUG:** Cabazitaxel

## Key facts

- **NCT ID:** NCT04709276
- **Lead sponsor:** Andrew J. Armstrong, MD
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2021-06-07
- **Primary completion:** 2026-02-26
- **Final completion:** 2028-08
- **Target enrollment:** 41 (ACTUAL)
- **Last updated:** 2026-04-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04709276

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04709276, "A Study of Chemoimmunotherapy for the Treatment of Men With Neuroendocrine or Aggressive Variant Metastatic Prostate Cancer". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT04709276. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*